NCT00005949View on ClinicalTrials.gov

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

March 31, 2006

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

aldesleukin

Given SC

BIOLOGICAL

gp100:209-217(210M) peptide vaccine

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005949 - Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter